Subscribe to the Daily PV Brief for breaking drug safety news, regulatory updates, and pharmacovigilance insights.
Daily News and Intelligence for the Pharmacovigilance Industry
Stay informed with timely coverage of drug safety, regulatory developments, safety signals, inspections, AI in pharmacovigilance, compliance trends, and career insights from across the global PV landscape.
Why Regulators Are Building Always-On Safety Information Hubs
AEMS pages, biologics safety pages, and standing communications hubs suggest regulators are moving toward more continuous public-facing safety visibility.
Today in PV
A quick scan of the latest stories, safety concerns, regulatory developments, and industry signals every pharmacovigilance professional should know today.
Explore Coverage
Browse the key areas shaping pharmacovigilance today, from global regulatory updates to safety signals, compliance trends, AI, and career growth.
Regulatory Updates
Track key developments from FDA, EMA, MHRA, WHO, NAFDAC, Health Canada, TGA, SAHPRA, and other health authorities.
Inspections & Compliance
Stay current on inspection readiness, CAPAs, SOP expectations, audit trends, and the compliance issues shaping PV systems.
Explainers
Clear, practical breakdowns of PV concepts, industry terms, reporting frameworks, and regulatory changes.
Careers
Insights for professionals building or advancing careers in pharmacovigilance, drug safety, compliance, and related functions.
Safety Signals
Follow emerging risks, label changes, recalls, medication errors, and other safety issues that matter in real-world pharmacovigilance.
AI & Digital PV
Explore how artificial intelligence, automation, and digital tools are influencing case processing, signal detection, and safety operations.
Latest News
Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam. Aque ipsa quae ab illo inventore veritatis. Sed ut perspiciatis unde omnis iste natus error sit voluptatem accus antium doloremque.
Why Regulators Are Building Always-On Safety Information Hubs
AEMS pages, biologics safety pages, and standing communications hubs suggest regulators are moving toward more continuous public-facing safety visibility.
CVMP March 2026 Highlights Keep Veterinary Safety in View
EMA’s March 2026 veterinary committee highlights are a useful reminder that regulatory safety visibility is active in animal health too.
EMA’s ESMP Training Push Signals More Structured Shortage Reporting
EMA’s new ESMP training session suggests shortage reporting is becoming a more structured and system-driven process for industry.
EMA Adds Anktiva to Additional Monitoring List in March 2026
EMA’s March 2026 additional monitoring update added Anktiva, reminding readers how closely new or conditionally authorised products are watched.
Rabies Immunoglobulin Recall Follows Potency Stability Failure
A UK recall of Human Rabies Immunoglobulin after reduced potency highlights how stability failures can become urgent safety and effectiveness issues.
FDA Warns 30 Telehealth Firms Over Compounded GLP-1 Claims
FDA has issued 30 warning letters to telehealth companies over false or misleading claims tied to compounded GLP-1 products.
Featured Posts
CVMP March 2026 Highlights Keep Veterinary Safety in View
EMA’s March 2026 veterinary committee highlights are a useful reminder that regulatory safety visibility is active in animal health too.
EMA Adds Anktiva to Additional Monitoring List in March 2026
EMA’s March 2026 additional monitoring update added Anktiva, reminding readers how closely new or conditionally authorised products are watched.
MHRA and NICE Launch Faster Joint Approval Pathway
MHRA and NICE say their new aligned pathway could bring some medicines to patients in England three to six months earlier.
Why Regulators Are Building Always-On Safety Information Hubs
AEMS pages, biologics safety pages, and standing communications hubs suggest regulators are moving toward more continuous public-facing safety visibility.
FDA Warns 30 Telehealth Firms Over Compounded GLP-1 Claims
FDA has issued 30 warning letters to telehealth companies over false or misleading claims tied to compounded GLP-1 products.
What EMA’s 2026 Biologics Safety Page Signals About Ongoing Regulator Transparency
FDA’s 2026 biologics safety-and-availability communications page is a small but telling sign of how regulators are organizing ongoing public visibility around risk and availability.
Why Real-Time Safety Visibility Is Becoming a Regulatory Strategy
Between AEMS, public dashboards, and standing safety communication pages, regulators are building a more visible safety-information environment.
PRAC Reviewed 140 PSUR Recommendations in January 2026: What That Tells Us
EMA’s January 2026 PRAC statistics offer a useful reminder that much of pharmacovigilance is steady, high-volume regulatory review rather than dramatic safety headlines.
Why EMA’s MSSG Matters When Shortages Become Safety Issues
EMA’s MSSG shows how supply, quality, safety, and crisis oversight increasingly overlap when shortages escalate.
Contact us
Email Us
editor@pvwatchdaily.com